Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control

Open access

Abstract

Obesity is a leading cause of preventable death worldwide. Despite this, current strategies for the treatment of obesity remain ineffective at achieving long‐term weight control. This is due, in part, to difficulties in identifying tolerable and efficacious small molecules or biologics capable of regulating systemic nutrient homeostasis. Here, we demonstrate that BAM15, a mitochondrially targeted small molecule protonophore, stimulates energy expenditure and glucose and lipid metabolism to protect against diet‐induced obesity. Exposure to BAM15 in vitro enhanced mitochondrial respiratory kinetics, improved insulin action, and stimulated nutrient uptake by sustained activation of AMPK. C57BL/6J mice treated with BAM15 were resistant to weight gain. Furthermore, BAM15‐treated mice exhibited improved body composition and glycemic control independent of weight loss, effects attributable to drug targeting of lipid‐rich tissues. We provide the first phenotypic characterization and demonstration of pre‐clinical efficacy for BAM15 as a pharmacological approach for the treatment of obesity and related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202012088

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure EV1 Related to Fig 1. BAM15 improves cellular respiratory kinetics by sustained mitochondrial uncoupling ANADH dehydrogenase activity in C2C12 cells following 16‐h treatment with varying concentrations of BAM15 (μM) (N = 7 per condition).B, C(B) Mitochondrial respiratory kinetics following acute injection of 1 μM BAM15, FCCP, or DNP into AML12 hepatocytes and (C) 3T3‐L1 adipocytes (N = 5 per condition).D–JAssessment of intact oxygen consumption rates (OCR) in C2C12 cells after serial injection of oligomycin, FCCP, and a cocktail of rotenone and antimycin A following overnight incubation with 0 (vehicle; 0.01% DMSO), 1.25, 10, or 20 μM BAM15 (N = 5 per condition). Basal: vehicle versus 10 μM: P = 0.037, vehicle versus 20 μM: P = 0.0072. Proton leak: vehicle versus 10 μM: P = 0.0002, vehicle versus 20 μM: P < 0.0001. Coupling efficiency: vehicle versus 10 μM: P < 0.0001, vehicle versus 20 μM: P < 0.0001. Spare respiratory capacity: vehicle versus 20 μM: P = 0.0179. Maximal respiration: vehicle versus 10 μM: P = 0.0192.K, LAssessment of intact extracellular acidification rates (ECAR) in C2C12 cells after serial injection of glucose, oligomycin, and 2‐deoxyglucose after 16‐h treatment with 0 (vehicle; 0.01% DMSO) or 20 μM BAM15 (N = 10 per condition).Data information: Data are shown as the mean ± SEM. *P < 0.05, ***P < 0.01, ****P < 0.001. Comparisons of treatment × time were assessed by one‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Comparisons of treatment alone were assessed by an unpaired Student's t‐test.
Figure EV1 Related to Fig 1. BAM15 improves cellular respiratory kinetics by sustained mitochondrial uncoupling ANADH dehydrogenase activity in C2C12 cells following 16‐h treatment with varying concentrations of BAM15 (μM) (N = 7 per condition).B, C(B) Mitochondrial respiratory kinetics following acute injection of 1 μM BAM15, FCCP, or DNP into AML12 hepatocytes and (C) 3T3‐L1 adipocytes (N = 5 per condition).D–JAssessment of intact oxygen consumption rates (OCR) in C2C12 cells after serial injection of oligomycin, FCCP, and a cocktail of rotenone and antimycin A following overnight incubation with 0 (vehicle; 0.01% DMSO), 1.25, 10, or 20 μM BAM15 (N = 5 per condition). Basal: vehicle versus 10 μM: P = 0.037, vehicle versus 20 μM: P = 0.0072. Proton leak: vehicle versus 10 μM: P = 0.0002, vehicle versus 20 μM: P < 0.0001. Coupling efficiency: vehicle versus 10 μM: P < 0.0001, vehicle versus 20 μM: P < 0.0001. Spare respiratory capacity: vehicle versus 20 μM: P = 0.0179. Maximal respiration: vehicle versus 10 μM: P = 0.0192.K, LAssessment of intact extracellular acidification rates (ECAR) in C2C12 cells after serial injection of glucose, oligomycin, and 2‐deoxyglucose after 16‐h treatment with 0 (vehicle; 0.01% DMSO) or 20 μM BAM15 (N = 10 per condition).Data information: Data are shown as the mean ± SEM. *P < 0.05, ***P < 0.01, ****P < 0.001. Comparisons of treatment × time were assessed by one‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Comparisons of treatment alone were assessed by an unpaired Student's t‐test.CC BY · PubMed Central
Figure 1 BAM15 improves cellular respiratory kinetics by sustained mitochondrial uncoupling. BAM15 improves cellular respiratory kinetics by sustained mitochondrial uncoupling ACaspase 3/7 activation ± 16‐h treatment with varying concentrations of BAM15, DNP, or FCCP (N = 3 per condition). 5 μM: BAM15 versus DNP (P = 0.030). 10 μM: BAM15 versus DNP (P = 0.013). 20 μM: BAM15 versus DNP (P = 0.0005), BAM15 versus FCCP (P = 0.036). 40 μM: BAM15 versus DNP (P = 0.018), BAM15 versus FCCP (P = 0.021). 80 μM: BAM15 versus DNP (P = 0.018), DNP versus FCCP (P = 0.004).B–F(B) The rate of oxygen consumption (OCR), (C) ratio of oxygen consumption to extracellular acidification (OCR/ECAR), (D) maximal rate of OCR (BAM15 versus DNP, P < 0.0001; DNP versus FCCP (P < 0.0001), (E) time to maximal uncoupling rate (BAM15 versus DNP, P < 0.0001; BAM15 versus FCCP (P < 0.0001), and (F) mitochondrial respiratory half‐life following acute injection of 1 μM BAM15, DNP, or FCCP (BAM15 versus DNP, P < 0.0001; BAM15 versus FCCP) (P < 0.0001) (N = 6 per condition).G, H(G) Representative respirometry plot of intact cells ± 16‐h treatment with 20 μM BAM15 sequentially injected with oligomycin, FCCP, and a cocktail of rotenone and antimycin a (N = 5 per condition) and (H) basal (P = 0.002) and ATP‐linked respiration, proton leak (P = 0.0003), maximal uncoupling, spare respiratory capacity (P < 0.0001), and non‐mitochondrial respiration (N = 5 per condition).IAssessment of routine (R) oxygen flux (P = 0.030), leak (L) (P = 0.010), OXPHOS (P), and ETC. (E) capacity in permeabilized C2C12 cells ± 16‐h treatment with BAM15 (N = 4 per condition). PM: pyruvate and malate, ADP: adenosine diphosphate, GS: glutamate and succinate, Tm: tetramethyl‐p‐phenylenediamine.JCitrate synthase activity ± 16‐h treatment with 20 μM BAM15 (N = 10 per condition).KmtDNA (COX2:18S) ± 16‐h treatment with 20 μM BAM15 (N = 6 per condition).Data information. Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels A, H, and I were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels D, E, and F were assessed by one‐way ANOVA with Tukey's multiple comparisons. Panels J and K were assessed by unpaired Student's t‐test.
Figure 1 BAM15 improves cellular respiratory kinetics by sustained mitochondrial uncoupling. BAM15 improves cellular respiratory kinetics by sustained mitochondrial uncoupling ACaspase 3/7 activation ± 16‐h treatment with varying concentrations of BAM15, DNP, or FCCP (N = 3 per condition). 5 μM: BAM15 versus DNP (P = 0.030). 10 μM: BAM15 versus DNP (P = 0.013). 20 μM: BAM15 versus DNP (P = 0.0005), BAM15 versus FCCP (P = 0.036). 40 μM: BAM15 versus DNP (P = 0.018), BAM15 versus FCCP (P = 0.021). 80 μM: BAM15 versus DNP (P = 0.018), DNP versus FCCP (P = 0.004).B–F(B) The rate of oxygen consumption (OCR), (C) ratio of oxygen consumption to extracellular acidification (OCR/ECAR), (D) maximal rate of OCR (BAM15 versus DNP, P < 0.0001; DNP versus FCCP (P < 0.0001), (E) time to maximal uncoupling rate (BAM15 versus DNP, P < 0.0001; BAM15 versus FCCP (P < 0.0001), and (F) mitochondrial respiratory half‐life following acute injection of 1 μM BAM15, DNP, or FCCP (BAM15 versus DNP, P < 0.0001; BAM15 versus FCCP) (P < 0.0001) (N = 6 per condition).G, H(G) Representative respirometry plot of intact cells ± 16‐h treatment with 20 μM BAM15 sequentially injected with oligomycin, FCCP, and a cocktail of rotenone and antimycin a (N = 5 per condition) and (H) basal (P = 0.002) and ATP‐linked respiration, proton leak (P = 0.0003), maximal uncoupling, spare respiratory capacity (P < 0.0001), and non‐mitochondrial respiration (N = 5 per condition).IAssessment of routine (R) oxygen flux (P = 0.030), leak (L) (P = 0.010), OXPHOS (P), and ETC. (E) capacity in permeabilized C2C12 cells ± 16‐h treatment with BAM15 (N = 4 per condition). PM: pyruvate and malate, ADP: adenosine diphosphate, GS: glutamate and succinate, Tm: tetramethyl‐p‐phenylenediamine.JCitrate synthase activity ± 16‐h treatment with 20 μM BAM15 (N = 10 per condition).KmtDNA (COX2:18S) ± 16‐h treatment with 20 μM BAM15 (N = 6 per condition).Data information. Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels A, H, and I were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels D, E, and F were assessed by one‐way ANOVA with Tukey's multiple comparisons. Panels J and K were assessed by unpaired Student's t‐test.CC BY · PubMed Central
Figure 2 BAM15 alters the expression of metabolic genes related to energy homeostasis AHeat map visualization of top 30 differentially regulated mRNA transcripts. Color represents significant downregulated (blue) or upregulated (red) mRNA expressed as a log2 fold change relative to vehicle corrected for the false discovery rate.BSchematic illustration of differentially regulated mRNA transcripts involved in the AMPK signaling pathway. Structures highlighted in shades of red were differentially regulated by BAM15. Darker shades of red correlate with increased probability of activation. Structures highlighted in gray or with black borders were unaltered by BAM15.CPathway enrichment analysis of differentially regulated mRNA transcripts.
Figure 2 BAM15 alters the expression of metabolic genes related to energy homeostasis AHeat map visualization of top 30 differentially regulated mRNA transcripts. Color represents significant downregulated (blue) or upregulated (red) mRNA expressed as a log2 fold change relative to vehicle corrected for the false discovery rate.BSchematic illustration of differentially regulated mRNA transcripts involved in the AMPK signaling pathway. Structures highlighted in shades of red were differentially regulated by BAM15. Darker shades of red correlate with increased probability of activation. Structures highlighted in gray or with black borders were unaltered by BAM15.CPathway enrichment analysis of differentially regulated mRNA transcripts.CC BY · PubMed Central
Figure 3 BAM15 stimulates insulin signaling and oxidation of glucose and fatty acids in an AMPK‐dependent manner A–D(A) Representative immunoblots and (B) quantitative analysis of AKT (1 μM insulin: P = 0.038), (C) AS160 (‐ insulin: P = 0.036, 1 μM insulin: P = 0.0038), and (D) AMPK (‐ insulin: P = 0.018) phosphorylation ± 16‐h BAM15 treatment and 15‐min insulin stimulation (N = 3 per condition) in C2C12 myotubes.E, F(E) Representative immunoblots and quantitative analysis of (F) plasma membrane GLUT4 translocation (P = 0.0139) ± 16‐h BAM15 treatment (N = 3 per condition) in C2C12 myotubes.G, H(G) [3‐3H]glucose uptake ± 16‐h BAM15 treatment and 30‐min insulin stimulation (N = 4 per condition; vehicle versus vehicle + insulin: P = 0.0016, vehicle versus BAM15: P < 0.0001, vehicle versus BAM15 + insulin: P < 0.0001, vehicle + insulin versus BAM15 + insulin: P = 0.0018, BAM15 versus BAM15 + insulin: P = 0.0024) and (H) [1‐14C]palmitate oxidation ± 16‐h BAM15 treatment and 5 mM glucose and 1 mM pyruvate (N = 6 per condition; no glucose/pyruvate: P < 0.0001) in C2C12 myotubes.IRepresentative immunoblot and quantitative analysis (N = 5 per condition; P < 0.0001) of AMPK demonstrating loss of function following transfection with an shAMPK construct in C2C12 myotubes.J, K(J) Representative respirometry plot of intact cells ± shAMPK and 16‐h BAM15 treatment in C2C12 myotubes cells sequentially injected with oligomycin, FCCP, and a cocktail of rotenone and antimycin a (N = 5 per condition) and (K) basal and ATP‐linked respiration, proton leak, maximal uncoupling, and spare respiratory capacity (N = 5 per condition). Basal: shEV versus shEV + BAM15 (P = 0.0317), shEV + BAM15 versus shAMPK (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001). ATP: shEV versus shAMPK + BAM15 (P = 0.0026), shEV + BAM15 versus shAMPK + BAM15 (P = 0.0003), shAMPK versus shAMPK + BAM15 (P = 0.040). Proton leak: shEV versus shEV + BAM15 (P = 0.0052), shAMPK versus shAMPK + BAM15 (P = 0.0394). Maximal: shEV versus shAMPK + BAM15 (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001), shAMPK versus shAMPK + BAM15 (P < 0.0001). Spare capacity: shEV versus shAMPK (P = 0.0028), shEV versus shAMPK + BAM15 (P < 0.0001), shEV + BAM15 versus shAMPK (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001), shAMPK versus shAMPK + BAM15 (P < 0.0001).L[3‐3H]glucose uptake ± shAMPK, 16‐h BAM15 treatment, and 30‐min insulin stimulation in C2C12 myotubes (N = 3 per condition). No insulin: shEV versus shEV + BAM15 (P = 0.0001). Insulin: shEV versus shEV + BAM15 (P = 0.0142).M–O(M) Representative immunoblots and quantitative analysis of (N) AKT (shEV + insulin: P = 0.0128, shAMPK ‐ insulin: P = 0.0018, shAMPK + insulin, P = 0.0124), and (O) AS160 (shEV – insulin: P = 0.0283, shEV + insulin: P = 0.0137) phosphorylation ± shAMPK, 16‐h BAM15 treatment, and 15‐min insulin stimulation in C2C12 myotubes (N = 3 per condition).Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels B, C, D, H, K, L, N, and O were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panel G was assessed by one‐way ANOVA with Tukey's multiple comparisons. Panels F and I were assessed by unpaired Student's t‐test. Source data are available online for this figure.
Figure 3 BAM15 stimulates insulin signaling and oxidation of glucose and fatty acids in an AMPK‐dependent manner A–D(A) Representative immunoblots and (B) quantitative analysis of AKT (1 μM insulin: P = 0.038), (C) AS160 (‐ insulin: P = 0.036, 1 μM insulin: P = 0.0038), and (D) AMPK (‐ insulin: P = 0.018) phosphorylation ± 16‐h BAM15 treatment and 15‐min insulin stimulation (N = 3 per condition) in C2C12 myotubes.E, F(E) Representative immunoblots and quantitative analysis of (F) plasma membrane GLUT4 translocation (P = 0.0139) ± 16‐h BAM15 treatment (N = 3 per condition) in C2C12 myotubes.G, H(G) [3‐3H]glucose uptake ± 16‐h BAM15 treatment and 30‐min insulin stimulation (N = 4 per condition; vehicle versus vehicle + insulin: P = 0.0016, vehicle versus BAM15: P < 0.0001, vehicle versus BAM15 + insulin: P < 0.0001, vehicle + insulin versus BAM15 + insulin: P = 0.0018, BAM15 versus BAM15 + insulin: P = 0.0024) and (H) [1‐14C]palmitate oxidation ± 16‐h BAM15 treatment and 5 mM glucose and 1 mM pyruvate (N = 6 per condition; no glucose/pyruvate: P < 0.0001) in C2C12 myotubes.IRepresentative immunoblot and quantitative analysis (N = 5 per condition; P < 0.0001) of AMPK demonstrating loss of function following transfection with an shAMPK construct in C2C12 myotubes.J, K(J) Representative respirometry plot of intact cells ± shAMPK and 16‐h BAM15 treatment in C2C12 myotubes cells sequentially injected with oligomycin, FCCP, and a cocktail of rotenone and antimycin a (N = 5 per condition) and (K) basal and ATP‐linked respiration, proton leak, maximal uncoupling, and spare respiratory capacity (N = 5 per condition). Basal: shEV versus shEV + BAM15 (P = 0.0317), shEV + BAM15 versus shAMPK (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001). ATP: shEV versus shAMPK + BAM15 (P = 0.0026), shEV + BAM15 versus shAMPK + BAM15 (P = 0.0003), shAMPK versus shAMPK + BAM15 (P = 0.040). Proton leak: shEV versus shEV + BAM15 (P = 0.0052), shAMPK versus shAMPK + BAM15 (P = 0.0394). Maximal: shEV versus shAMPK + BAM15 (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001), shAMPK versus shAMPK + BAM15 (P < 0.0001). Spare capacity: shEV versus shAMPK (P = 0.0028), shEV versus shAMPK + BAM15 (P < 0.0001), shEV + BAM15 versus shAMPK (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001), shAMPK versus shAMPK + BAM15 (P < 0.0001).L[3‐3H]glucose uptake ± shAMPK, 16‐h BAM15 treatment, and 30‐min insulin stimulation in C2C12 myotubes (N = 3 per condition). No insulin: shEV versus shEV + BAM15 (P = 0.0001). Insulin: shEV versus shEV + BAM15 (P = 0.0142).M–O(M) Representative immunoblots and quantitative analysis of (N) AKT (shEV + insulin: P = 0.0128, shAMPK ‐ insulin: P = 0.0018, shAMPK + insulin, P = 0.0124), and (O) AS160 (shEV – insulin: P = 0.0283, shEV + insulin: P = 0.0137) phosphorylation ± shAMPK, 16‐h BAM15 treatment, and 15‐min insulin stimulation in C2C12 myotubes (N = 3 per condition).Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels B, C, D, H, K, L, N, and O were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panel G was assessed by one‐way ANOVA with Tukey's multiple comparisons. Panels F and I were assessed by unpaired Student's t‐test. Source data are available online for this figure.CC BY · PubMed Central
Figure EV2 Related to Fig 4. BAM15 prevents diet‐induced obesity by increasing energy expenditure in C57BL/6J mice ARepresentative image of a CTRL‐ and BAM15‐treated animal at time of necropsy.B, C(B) Daily consumption (N = 16 per group) and (C) tissue distribution of BAM15 over a 24‐h feeding period (N = 3 per time point).D, E(D) Daily food intake over the 3‐week treatment period (N = 16 per group) and (E) mean food intake expressed relative to body weight (N = 16 per group; P = 0.0275).FRelationship between body temperature and weight after 3 weeks of treatment (N = 16).G, H(G) Representative thermal image of a mouse exposed to 0, 6, 12, and 24 h of BAM15 (TP = 0, 6, 12, and 24, respectively). Scale bar (right of image) represents 22–32° (dark blue to white) temperature range. (H) Tail heat dissipation of mice exposed to 0, 6, 12, and 24 h of BAM15 (N = 6 per time point).IGlucose concentrations in response to IPGTT expressed as a percent of baseline (N = 8 per group; 120 min: P = 0.0413).J–L(J) Daily physical activity before (PRE) and 3 weeks (POST) of CTRL or BAM15 treatment (N = 8 per group; CTRL PRE–POST: P < 0.0001) and (K) cumulative physical activity following 3 weeks of CTRL or BAM15 treatment (N = 8 per group). (L) Cumulative water consumption over a 7‐day period ((N = 8 per group).Data information: Data are shown as the mean ± SEM. *P < 0.05, ****P < 0.001. Comparisons of treatment × time were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels J‐L were assessed by a repeated‐measures ANOVA with body weight as a covariate. Comparisons of treatment alone were assessed by an unpaired Student's t‐test. Bivariate relationships were determined by linear regression modeling followed by statistical evaluation with Pearson's r. Dotted lines represent 95% confidence intervals.
Figure EV2 Related to Fig 4. BAM15 prevents diet‐induced obesity by increasing energy expenditure in C57BL/6J mice ARepresentative image of a CTRL‐ and BAM15‐treated animal at time of necropsy.B, C(B) Daily consumption (N = 16 per group) and (C) tissue distribution of BAM15 over a 24‐h feeding period (N = 3 per time point).D, E(D) Daily food intake over the 3‐week treatment period (N = 16 per group) and (E) mean food intake expressed relative to body weight (N = 16 per group; P = 0.0275).FRelationship between body temperature and weight after 3 weeks of treatment (N = 16).G, H(G) Representative thermal image of a mouse exposed to 0, 6, 12, and 24 h of BAM15 (TP = 0, 6, 12, and 24, respectively). Scale bar (right of image) represents 22–32° (dark blue to white) temperature range. (H) Tail heat dissipation of mice exposed to 0, 6, 12, and 24 h of BAM15 (N = 6 per time point).IGlucose concentrations in response to IPGTT expressed as a percent of baseline (N = 8 per group; 120 min: P = 0.0413).J–L(J) Daily physical activity before (PRE) and 3 weeks (POST) of CTRL or BAM15 treatment (N = 8 per group; CTRL PRE–POST: P < 0.0001) and (K) cumulative physical activity following 3 weeks of CTRL or BAM15 treatment (N = 8 per group). (L) Cumulative water consumption over a 7‐day period ((N = 8 per group).Data information: Data are shown as the mean ± SEM. *P < 0.05, ****P < 0.001. Comparisons of treatment × time were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels J‐L were assessed by a repeated‐measures ANOVA with body weight as a covariate. Comparisons of treatment alone were assessed by an unpaired Student's t‐test. Bivariate relationships were determined by linear regression modeling followed by statistical evaluation with Pearson's r. Dotted lines represent 95% confidence intervals.CC BY · PubMed Central
Figure 4 BAM15 prevents diet‐induced obesity by increasing energy expenditure in C57BL/6J mice A, B(A) Serum concentrations of BAM15 over a 24‐h period (N = 3 animals per time point) and (B) peak tissue concentrations of BAM15 (N = 6 per tissue).C, D(C) Daily body weight (day 8: P = 0.0454, day 9: P = 0.0353, day 10: P = 0.0251, day 11: P = 0.0131, day 12: 0.0038, day 13: P = 0.0008, day 14: P = 0.0005, day 15: P = 0.0003, day 16–21: P < 0.0001) and (D) cumulative food intake over the 3‐week treatment in CTRL‐ and BAM15‐treated animals (N = 16 per group).E, F(E) Whole‐body temperature before (pre), 1 h (1 h post), and 24 h (24 h post) after intraperitoneal injection of corn oil, vehicle (corn oil and saline), 0.1, 0.5, and, 1 mg BAM15 per kg of body weight (N = 11 per group), and (F) daily during chronic BAM15 treatment (N = 8 per group).G, H(G) Change in fat mass (%) (P < 0.0001) and (H) lean mass (%) (P < 0.0001) from baseline to 3 weeks in CTRL‐ and BAM15‐treated animals (N = 8 per group).I–L(I) Fasting plasma glucose (N = 8 per group; P = 0.007) and (J) insulin (N = 7 per group; P = 0.0024) after 3 weeks of treatment in CTRL‐ and BAM15‐treated animals. (K) Plasma glucose concentrations at 0, 15, 30, 60, 90, and 120 min following intraperitoneal injection of glucose (2 g glucose/kg of body weight; N = 8 per group) and (L) total area under the curve glucose after 3 weeks in CTRL‐ and BAM15‐treated animals (N = 8 per group; P = 0.0106).M–O(M) Oxygen consumption rates (N) energy expenditure (daily: P = 0.0357, dark phase: P = 0.030), and (O) respiratory exchange ratio (daily: P = 0.0424, dark phase: P = 0.0016) measured by continuous high‐resolution indirect calorimetry after 3 weeks of CTRL or BAM15 treatment (N = 8 per group).PFecal energy density (% recovered in feces) after 3 weeks of CTRL or BAM15 treatment (N = 8 per group).Data information: Data are shown as the mean ± SEM with exception to panel B with exception to panels E, H, and G which are displayed as a box (mean ± 5–95% CI) and whiskers (minimum to maximum) plot. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels C, D, E, F, N, and O were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels G, H, I, J, L, and P were assessed by an unpaired Student's t‐test.
Figure 4 BAM15 prevents diet‐induced obesity by increasing energy expenditure in C57BL/6J mice A, B(A) Serum concentrations of BAM15 over a 24‐h period (N = 3 animals per time point) and (B) peak tissue concentrations of BAM15 (N = 6 per tissue).C, D(C) Daily body weight (day 8: P = 0.0454, day 9: P = 0.0353, day 10: P = 0.0251, day 11: P = 0.0131, day 12: 0.0038, day 13: P = 0.0008, day 14: P = 0.0005, day 15: P = 0.0003, day 16–21: P < 0.0001) and (D) cumulative food intake over the 3‐week treatment in CTRL‐ and BAM15‐treated animals (N = 16 per group).E, F(E) Whole‐body temperature before (pre), 1 h (1 h post), and 24 h (24 h post) after intraperitoneal injection of corn oil, vehicle (corn oil and saline), 0.1, 0.5, and, 1 mg BAM15 per kg of body weight (N = 11 per group), and (F) daily during chronic BAM15 treatment (N = 8 per group).G, H(G) Change in fat mass (%) (P < 0.0001) and (H) lean mass (%) (P < 0.0001) from baseline to 3 weeks in CTRL‐ and BAM15‐treated animals (N = 8 per group).I–L(I) Fasting plasma glucose (N = 8 per group; P = 0.007) and (J) insulin (N = 7 per group; P = 0.0024) after 3 weeks of treatment in CTRL‐ and BAM15‐treated animals. (K) Plasma glucose concentrations at 0, 15, 30, 60, 90, and 120 min following intraperitoneal injection of glucose (2 g glucose/kg of body weight; N = 8 per group) and (L) total area under the curve glucose after 3 weeks in CTRL‐ and BAM15‐treated animals (N = 8 per group; P = 0.0106).M–O(M) Oxygen consumption rates (N) energy expenditure (daily: P = 0.0357, dark phase: P = 0.030), and (O) respiratory exchange ratio (daily: P = 0.0424, dark phase: P = 0.0016) measured by continuous high‐resolution indirect calorimetry after 3 weeks of CTRL or BAM15 treatment (N = 8 per group).PFecal energy density (% recovered in feces) after 3 weeks of CTRL or BAM15 treatment (N = 8 per group).Data information: Data are shown as the mean ± SEM with exception to panel B with exception to panels E, H, and G which are displayed as a box (mean ± 5–95% CI) and whiskers (minimum to maximum) plot. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels C, D, E, F, N, and O were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels G, H, I, J, L, and P were assessed by an unpaired Student's t‐test.CC BY · PubMed Central
Figure EV3 Related to Fig 4. BAM15 prevents diet‐induced obesity by increasing energy expenditure in C57BL/6J mice A–LOrgan weights at time of necropsy following 3 weeks of CTRL or BAM15 treatment (N = 8 per group). Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Comparisons of treatment alone were assessed by an unpaired Student's t‐test. Bloodless body: P < 0.0001. Liver: P = 0.0257. iWAT: P < 0.0001. gWAT: P < 0.0001. rpWAT: P = 0.0002. BAT: P = 0.0064.
Figure EV3 Related to Fig 4. BAM15 prevents diet‐induced obesity by increasing energy expenditure in C57BL/6J mice A–LOrgan weights at time of necropsy following 3 weeks of CTRL or BAM15 treatment (N = 8 per group). Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Comparisons of treatment alone were assessed by an unpaired Student's t‐test. Bloodless body: P < 0.0001. Liver: P = 0.0257. iWAT: P < 0.0001. gWAT: P < 0.0001. rpWAT: P = 0.0002. BAT: P = 0.0064.CC BY · PubMed Central
Figure 5 BAM15 improves body composition and glycemic control independent of weight loss in C57BL/6J mice. BAM15 improves body composition and glycemic control independent of weight loss in C57BL/6J mice A–D(A) Change in body weight (CTRL versus BAM15: P < 0.0001, CTRL versus CR: P < 0.0001), (B) fat mass (CTRL versus BAM15: P = 0.0005, CTRL versus CR: P = 0.0041, BAM15 versus CR: P = 0.043), and (C) lean mass (CTRL versus BAM15: P = 0.0014, CTRL versus CR: P < 0.0001, BAM15 versus CR: P = 0.0047) from baseline to 2 weeks in CTRL‐, BAM15‐, and CR‐treated animals and (D) daily food intake (CTRL versus CR: P = 0.0092, BAM15 versus CR: P = 0.0175) in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8).E, F(E) Blood glucose concentrations at 0, 15, 30, 60, 90, and 120 min following intraperitoneal injection of glucose (2 g glucose/kg of body weight; N = 8 per group) and (F) total area under the curve glucose (CTRL versus BAM15: P < 0.0001, CTRL versus CR: P = 0.003, BAM15 versus CR: P = 0.0261) after 2 weeks of treatment in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8).G, H(G) Plasma insulin concentrations at baseline (PRE), and 0 (CTRL versus BAM15: P = 0.0154, CTRL versus CR: P = 0.0425) and 120 min (CTRL versus BAM15: P = 0.0005, CTRL versus CR: P = 0.0211, BAM15 versus CR: P = 0.0264) after injection of glucose after 2 weeks of treatment in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8) and (H) Homeostatic Model Assessment of Insulin Resistance (HOMA‐IR) (CTRL versus BAM15: P = 0.0259, CTRL versus CR: P = 0.040) after 2 weeks of treatment in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8).Data information: Data are shown as the mean ± SEM with exception to panels A, B, and C which are displayed as a box (mean ± 5‐95% CI) and whiskers (minimum to maximum). *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panel G was assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels A, B, C, D, F, and H were assessed by one‐way ANOVA with Tukey's multiple comparisons.
Figure 5 BAM15 improves body composition and glycemic control independent of weight loss in C57BL/6J mice. BAM15 improves body composition and glycemic control independent of weight loss in C57BL/6J mice A–D(A) Change in body weight (CTRL versus BAM15: P < 0.0001, CTRL versus CR: P < 0.0001), (B) fat mass (CTRL versus BAM15: P = 0.0005, CTRL versus CR: P = 0.0041, BAM15 versus CR: P = 0.043), and (C) lean mass (CTRL versus BAM15: P = 0.0014, CTRL versus CR: P < 0.0001, BAM15 versus CR: P = 0.0047) from baseline to 2 weeks in CTRL‐, BAM15‐, and CR‐treated animals and (D) daily food intake (CTRL versus CR: P = 0.0092, BAM15 versus CR: P = 0.0175) in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8).E, F(E) Blood glucose concentrations at 0, 15, 30, 60, 90, and 120 min following intraperitoneal injection of glucose (2 g glucose/kg of body weight; N = 8 per group) and (F) total area under the curve glucose (CTRL versus BAM15: P < 0.0001, CTRL versus CR: P = 0.003, BAM15 versus CR: P = 0.0261) after 2 weeks of treatment in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8).G, H(G) Plasma insulin concentrations at baseline (PRE), and 0 (CTRL versus BAM15: P = 0.0154, CTRL versus CR: P = 0.0425) and 120 min (CTRL versus BAM15: P = 0.0005, CTRL versus CR: P = 0.0211, BAM15 versus CR: P = 0.0264) after injection of glucose after 2 weeks of treatment in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8) and (H) Homeostatic Model Assessment of Insulin Resistance (HOMA‐IR) (CTRL versus BAM15: P = 0.0259, CTRL versus CR: P = 0.040) after 2 weeks of treatment in CTRL‐, BAM15‐, and CR‐treated animals (CTRL N = 7, BAM15 and CR N = 8).Data information: Data are shown as the mean ± SEM with exception to panels A, B, and C which are displayed as a box (mean ± 5‐95% CI) and whiskers (minimum to maximum). *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panel G was assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels A, B, C, D, F, and H were assessed by one‐way ANOVA with Tukey's multiple comparisons.CC BY · PubMed Central
Figure 6 BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice ARepresentative H&E‐stained liver, adipose tissue, and skeletal muscle sections from CTRL‐ and BAM15‐treated animals. Scale bars (black) = 100 μm.BRepresentative immunohistochemical analysis of pancreatic insulin (red) content counterstained with diaminobenzidine (blue). Scale bars (black) = 100 μm.C–F(C) Quantitative analysis of liver steatosis (μm2) (N = 6 per group; P < 0.0001), (D) gastrocnemius muscle cross‐sectional area (μm2) (CTRL N = 7, BAM15 N = 8), (E) pancreatic insulin‐positive area (% of total area) (N = 6 per group; P = 0.0420), (F) and β‐cell mass (N = 4 per group; P = 0.0005).G–ISize (area; μm2) and distributional (number) analysis of (G) iWAT, (H) gWAT, and (I) BAT from CTRL‐ and BAM15‐treated animals (N = 8 per group).Data information: Data are shown as the mean ± SEM. *P < 0.05, ***P < 0.01, ****P < 0.001. Panels C, D, E, and F were assessed by an unpaired Student's t‐test.
Figure 6 BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice ARepresentative H&E‐stained liver, adipose tissue, and skeletal muscle sections from CTRL‐ and BAM15‐treated animals. Scale bars (black) = 100 μm.BRepresentative immunohistochemical analysis of pancreatic insulin (red) content counterstained with diaminobenzidine (blue). Scale bars (black) = 100 μm.C–F(C) Quantitative analysis of liver steatosis (μm2) (N = 6 per group; P < 0.0001), (D) gastrocnemius muscle cross‐sectional area (μm2) (CTRL N = 7, BAM15 N = 8), (E) pancreatic insulin‐positive area (% of total area) (N = 6 per group; P = 0.0420), (F) and β‐cell mass (N = 4 per group; P = 0.0005).G–ISize (area; μm2) and distributional (number) analysis of (G) iWAT, (H) gWAT, and (I) BAT from CTRL‐ and BAM15‐treated animals (N = 8 per group).Data information: Data are shown as the mean ± SEM. *P < 0.05, ***P < 0.01, ****P < 0.001. Panels C, D, E, and F were assessed by an unpaired Student's t‐test.CC BY · PubMed Central
Figure EV4 Related to Fig 6. BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice. Related to Fig 6. BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice Representative H&E and trichrome staining of paraffin‐embedded tissue sections. Scale bars (black) = 100 μm with exception to testis (250 μm), seminal vesicles (500 μm), trachea (500 μm), lung (500 μm), tongue (2.5 mm), rectum (250 μm), and spleen (500 μm). Black arrow represents vacuole formation in the proximal tubules of the kidney. Representative H&E and trichrome staining of paraffin‐embedded tissue sections. Scale bars (black) = 100 μm with exception to testis (250 μm), seminal vesicles (500 μm), trachea (500 μm), lung (500 μm), tongue (2.5 mm), rectum (250 μm), and spleen (500 μm). Black arrow represents vacuole formation in the proximal tubules of the kidney.
Figure EV4 Related to Fig 6. BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice. Related to Fig 6. BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice Representative H&E and trichrome staining of paraffin‐embedded tissue sections. Scale bars (black) = 100 μm with exception to testis (250 μm), seminal vesicles (500 μm), trachea (500 μm), lung (500 μm), tongue (2.5 mm), rectum (250 μm), and spleen (500 μm). Black arrow represents vacuole formation in the proximal tubules of the kidney. Representative H&E and trichrome staining of paraffin‐embedded tissue sections. Scale bars (black) = 100 μm with exception to testis (250 μm), seminal vesicles (500 μm), trachea (500 μm), lung (500 μm), tongue (2.5 mm), rectum (250 μm), and spleen (500 μm). Black arrow represents vacuole formation in the proximal tubules of the kidney.CC BY · PubMed Central
Figure 7 Increased skeletal muscle fatty acid oxidation is supported by AMPK‐mediated suppression of lipogenesis in white adipose tissue following treatment with BAM15 A–D(A) Plasma concentrations of non‐esterified fatty acids (NEFAs) (CTRL N = 7, BAM15 N = 8, P = 0.0073), (B) leptin (N = 8 per group, P < 0.0001), (C) GDF15 (N = 7 per group, P = 0.035), and (D) FGF21 (N = 7 per group, P = 0.0026) after 3 weeks of CTRL or BAM15 treatment.E, F(E) Total (basal: P = 0.015) and (F) complete (basal: P = 0.0137) oxidation of 200 μM [1‐14C]palmitate to CO2 from mixed gastrocnemius muscle homogenates (N = 7 per group).GRoutine (R) oxygen flux, leak (L), OXPHOS (P), and ETC. (E) capacity in permeabilized mixed gastrocnemius fibers (N = 6 per group). PM: pyruvate and malate, ADP: adenosine diphosphate, GS: glutamate and succinate, Tm: tetramethyl‐p‐phenylenediamine, PalM: palmitoylcarnitine and malate, Oct: octanoylcarnitine, and Dur: duroquinol.H–K(H) Representative immunoblots of phosphorylated and total AMPK and ACC from iWAT, and mixed gastrocnemius muscle and (I‐K) densitometric quantification (N = 4 per group; iWAT p‐AMPKT172: P = 0.0186, iWAT p‐ACCS79: P = 0.0083, mixed gastrocnemius p‐AMPKT172: P = 0.0286).L–NmRNA expression of transcriptional regulators of lipogenesis and lipolysis in iWAT (N = 7 per group). Srebf1 (P < 0.0001), Mlxipl (P = 0.0018), Scd1 (P < 0.0001), FASN (P = 0.0009), LIPE (P = 0.0015), Pnpla2 (P < 0.0001), PPARg (P < 0.0001).Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels E, F, and G were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels A, B, C, D, I, J, K, L, M, and N were assessed by an unpaired Student's t‐test. Source data are available online for this figure.
Figure 7 Increased skeletal muscle fatty acid oxidation is supported by AMPK‐mediated suppression of lipogenesis in white adipose tissue following treatment with BAM15 A–D(A) Plasma concentrations of non‐esterified fatty acids (NEFAs) (CTRL N = 7, BAM15 N = 8, P = 0.0073), (B) leptin (N = 8 per group, P < 0.0001), (C) GDF15 (N = 7 per group, P = 0.035), and (D) FGF21 (N = 7 per group, P = 0.0026) after 3 weeks of CTRL or BAM15 treatment.E, F(E) Total (basal: P = 0.015) and (F) complete (basal: P = 0.0137) oxidation of 200 μM [1‐14C]palmitate to CO2 from mixed gastrocnemius muscle homogenates (N = 7 per group).GRoutine (R) oxygen flux, leak (L), OXPHOS (P), and ETC. (E) capacity in permeabilized mixed gastrocnemius fibers (N = 6 per group). PM: pyruvate and malate, ADP: adenosine diphosphate, GS: glutamate and succinate, Tm: tetramethyl‐p‐phenylenediamine, PalM: palmitoylcarnitine and malate, Oct: octanoylcarnitine, and Dur: duroquinol.H–K(H) Representative immunoblots of phosphorylated and total AMPK and ACC from iWAT, and mixed gastrocnemius muscle and (I‐K) densitometric quantification (N = 4 per group; iWAT p‐AMPKT172: P = 0.0186, iWAT p‐ACCS79: P = 0.0083, mixed gastrocnemius p‐AMPKT172: P = 0.0286).L–NmRNA expression of transcriptional regulators of lipogenesis and lipolysis in iWAT (N = 7 per group). Srebf1 (P < 0.0001), Mlxipl (P = 0.0018), Scd1 (P < 0.0001), FASN (P = 0.0009), LIPE (P = 0.0015), Pnpla2 (P < 0.0001), PPARg (P < 0.0001).Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels E, F, and G were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels A, B, C, D, I, J, K, L, M, and N were assessed by an unpaired Student's t‐test. Source data are available online for this figure.CC BY · PubMed Central
Figure EV5 Related to Fig 6. BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice A, B(A) Circulating adiponectin (N = 6 per group) and (B) beta‐hydroxybutyrate (BHB) (CTRL N = 7, BAM15 N = 8) concentrations in CTRL‐ and BAM15‐treated animals.CFatty acid oxidation attributable to acid‐soluble metabolites (ASM) in mixed gastrocnemius muscle ± 1 mM pyruvate (N = 7 per group).D, E(D) Ex vivo rates of glycerol release from iWAT and (E) gWAT in CTRAL‐ and BAM15‐treated animals (N = 8 per group).FRepresentative immunoblots of p‐AMPKT172 and AMPK from heart and liver homogenates and p‐ACCS79 and ACC from mixed gastrocnemius muscle.Data information: Data are shown as the mean ± SEM. Main effects of treatment × time were assessed by two‐way repeated‐measures ANOVA with Tukey's post hoc test. Main effects of treatment alone were assessed by unpaired Student's t‐test. Source data are available online for this figure.
Figure EV5 Related to Fig 6. BAM15 restricts adipose tissue expansion and lipid deposition to liver and kidney in C57BL/6J mice A, B(A) Circulating adiponectin (N = 6 per group) and (B) beta‐hydroxybutyrate (BHB) (CTRL N = 7, BAM15 N = 8) concentrations in CTRL‐ and BAM15‐treated animals.CFatty acid oxidation attributable to acid‐soluble metabolites (ASM) in mixed gastrocnemius muscle ± 1 mM pyruvate (N = 7 per group).D, E(D) Ex vivo rates of glycerol release from iWAT and (E) gWAT in CTRAL‐ and BAM15‐treated animals (N = 8 per group).FRepresentative immunoblots of p‐AMPKT172 and AMPK from heart and liver homogenates and p‐ACCS79 and ACC from mixed gastrocnemius muscle.Data information: Data are shown as the mean ± SEM. Main effects of treatment × time were assessed by two‐way repeated‐measures ANOVA with Tukey's post hoc test. Main effects of treatment alone were assessed by unpaired Student's t‐test. Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 89

Metadata

Authors
Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., Langohr, I., Stadler, K., Doyle, H., Schmidt, E., Nieuwoudt, S., Fitzgerald, K., Pergola, K., Fujioka, H., Mey, J. T., Fealy, C., Mulya, A., Beyl, R., Hoppel, C. L., & Kirwan, J. P.
Affiliations
  • Pennington Biomedical Research Center (US)
  • Cleveland Clinic (US)
  • UNSW Sydney (AU)
  • Louisiana State University (US)
  • Case Western Reserve University (US)
Corresponding author
Kirwan, John P
Venue
EMBO Molecular Medicine
Published
2020-06-10
Volume
12
Issue
7
Pages
e12088-e12088
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3032939189
Cited by
89
References
65
Citations by year
2026: 14 · 2025: 18 · 2024: 8 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 3
FWCI
7.34
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Civil War Book Review (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (DK108089, DK103860, DK115749, DK072476)
  • Department of Health|National Health and Medical Research Council (GNT1163903)
  • HHS|NIH|National Institute of General Medical Sciences (GM103528, GM104940)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
BAM15, mitochondrial uncoupling, protonophores, diet-induced obesity, energy expenditure, glucose metabolism, lipid metabolism, insulin sensitivity, AMPK activation, mitochondrial respiration, glycemic control, body composition, obesity treatment
MeSH terms
Glycemic Control, Animals, Energy Metabolism, Glucose, Insulin Resistance, Male, Mice, Inbred C57BL, Mitochondria, Obesity, Uncoupling Agents, Mice, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control. https://app.cochat.ai/papers/10.15252/emmm.202012088
The paper
Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., Langohr, I., Stadler, K., Doyle, H., Schmidt, E., Nieuwoudt, S., Fitzgerald, K., Pergola, K., Fujioka, H., Mey, J. T., . . . Kirwan, J. P. (2020). BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012088

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.